$9.46
-$0.05
(-0.53%)
Quote as of 4:00 PM EST on 02/13/12
Human Genome Sciences
NASDAQ:HGSI
|
$9.46
-$0.05
(-0.53%)
|
|
| Today's Open | $9.68 |
|---|---|
| Previous Close | $9.51 |
| Daily Range | $9.44 - $9.72 |
| 52-Week Range | $6.51 - $30.15 |
| Market Cap | $1.88B |
| P/E Ratio | -4.71 |
| Dividend (Yield) | $0.00 (0.0%) |
| Volume | 6,152,390 |
| Average Daily Volume | 8,494,987 |
| Current FY EPS | -$1.97 |
HGSI Information
| Description |
|---|
| The drug development company with three products advancing into late-stage clinical development: Albuferon(r) for chronic hepatitis C, LymphoStat-B(r) for systemic lupus erythematosus, and ABthraxtm for anthrax disease. |
| Sector |
| Healthcare |
| Industry |
| Biotechnology |
News & Commentary
Eyeing Biotech's Newest Darling
Is Avanir Pharmaceuticals the Perfect Stock?
Has GlaxoSmithKline Become the Perfect Stock?
Make Money in Dynamic Biotech Stocks the Easy Way
2-Star Stocks Poised to Plunge: Human Genome?
6 Key Drivers for Biotechnology's 2012 Outlook
This Just In: More Upgrades and Downgrades
No Vacancy: Workers Need Not Apply to This Sector
Buy, Sell, or Hold: Human Genome Sciences
